JNJ will use the money as it had been doing all the time - buy products and companies to boost its "revenue & profit"/share numbers. JNJ is strong in marketing, but it also has good financial people who are able to make the book looks good every quarter.
one way to make the book llok good is to reduce the # sh....i.e buyback shares. You certainly will not see insiders buy jnj stock with their own money.....heaven forbid. If mgmt doesn't want to buy back jnj sh then i say put the money on the colts.
Johnson & Johnson, based in New Brunswick, N.J., said it expects to post most of the payment as a special item in the first quarter. The companies are familiar patent case foes. In September, Boston Scientific agreed to pay Johnson & Johnson $716 million to settle 14 other patent infringement suits. (They also have a great patent litigation team) They should add a new business unit to the company. They seem to be getting pretty good results. BSX seems to be JNJ whipping boy. It doesn’t pay to cheat BSX. At least not with JNJ. Not a bad pay out...over $2.4B in less then 6 months